mRNA COVID-2019 vaccine - eTheRNA Immunotherapies
Latest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator eTheRNA Immunotherapies
- Class COVID-19 vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Belgium (Intranasal)
- 24 Mar 2020 Preclinical trials in COVID-2019 infections (Prevention) in Belgium (Intranasal)
- 24 Mar 2020 eTheRNA Immunotherapies plans clinical trial for COVID-2019 infections in early 2021